are you attributing the continuous decline in ENANTA to the slashing in hep-c drug by analysts or a possible acquisition by ABBV of ACHN?
if neither can you give your opinion as to why stock has a 600 mkt cap given a est 275 million in cash by end of qtr and royalties of 100-150 per year for 2015/2016/2017.